AZD4604 for Asthma
(ARTEMISIA Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma. Study details include: * The study duration for each participant will be approximately 10 weeks. * The duration of IMP administration will be approximately 4 weeks.
Do I need to stop my current medications to join the trial?
The trial requires participants to be on a stable dose of certain asthma medications, like medium-to-high dose inhaled corticosteroids and long-acting beta agonists, for at least 2 months before starting. However, you cannot be on systemic corticosteroids or certain other medications like immunosuppressive therapies and some biologics. It's best to discuss your current medications with the trial team to see if they fit the criteria.
Eligibility Criteria
This trial is for adults with moderate-to-severe asthma who are interested in testing a new treatment. Participants should be available for about 10 weeks and willing to take the study medication or placebo for around 4 weeks.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AZD4604 or placebo for 4 weeks to evaluate the effect on airway inflammation and JAK1-associated signalling pathways
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD4604 (JAK Inhibitor)